Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a hold rating in a report published on Saturday morning.

Several other equities analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Cantor Fitzgerald started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, July 24th. They set an “overweight” rating and a $11.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $6.60 on Friday. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $7.19. The stock has a market capitalization of $237.34 million, a price-to-earnings ratio of -7.59 and a beta of 1.47. The company’s 50 day moving average price is $5.82 and its 200-day moving average price is $5.14.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. As a group, equities research analysts forecast that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Trading of Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quadrature Capital Ltd bought a new stake in Eupraxia Pharmaceuticals during the 2nd quarter valued at approximately $61,000. TCI Wealth Advisors Inc. bought a new stake in shares of Eupraxia Pharmaceuticals during the third quarter valued at approximately $65,000. Integrated Wealth Concepts LLC purchased a new stake in Eupraxia Pharmaceuticals in the third quarter worth $71,000. Bank of America Corp DE grew its stake in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after purchasing an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after purchasing an additional 16,017 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.